Evidence map›Paper›PMID 41972146›Full record

ArticleFrontiers in immunology2026

Danthron as a novel IL-6R agonist promotes thrombopoiesis via the SRC/RAS/MAPK pathway.

Rui Liao, Jiesi Luo, Xiaoxuan Li, Xiaoqin Tang, Miao Huang, Ling Zhou, Long Yun, Zhixuan Liu, Peilian Jiang, Xinle Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rui Liao *Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Jiesi Luo *School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.
Xiaoxuan Li *Department of Pharmacy, The Second People's Hospital of Yibin, Yibin, China.
Xiaoqin TangSichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Miao HuangSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ling ZhouSichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Long YunSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zhixuan LiuSichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Peilian JiangSichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Xinle WangSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.
Xiaolin GanSichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Long WangSichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, China.
Jianming WuSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to investigate the effects of danthron on promoting megakaryocyte (MK) differentiation and alleviating thrombocytopenia, as well as to elucidate its underlying mechanisms. Methods: Cell proliferation and apoptosis of Meg-01 and K562 cells were evaluated by CCK-8, LDH release, and apoptosis assays. MK differentiation was assessed by Giemsa staining, phalloidin staining, and flow cytometry. A thrombocytopenia mouse model was induced by 4 Gy irradiation and treated intraperitoneally with danthron for 12 days, followed by hematological, histopathological, MK differentiation, and tail bleeding analyses. Potential targets and pathways were explored using network pharmacology, molecular docking, GO/KEGG enrichment, Western blotting, and inhibitor validation. Results: Danthron effectively promoted MK differentiation Conclusion: This study uncovered danthron as a novel natural small-molecule agonist of IL-6R and demonstrated its therapeutic potential in thrombocytopenia. The effect of danthron is mediated by its capacity to promote MK differentiation and induce platelet production through targeting of IL-6R and activation of the downstream SRC/RAS/MAPK signaling pathway. These results highlight danthron as a promising candidate for thrombocytopenia therapy and underscore the therapeutic potential of targeting IL-6R signaling for hematopoietic regulation.

Indexed as

MAP Kinase Signaling Systemsrc-Family KinasesThrombopoiesisAnimalsApoptosisCell DifferentiationCell ProliferationDisease Models, AnimalHumansK562 CellsMaleMegakaryocytesMiceras ProteinsSignal TransductionThrombocytopeniaras Proteinssrc-Family KinasesdanthronIL-6RmegakaryocyteplateletSRC/RAS/MAPKthrombocytopenia

Identifiers

PMID41972146
PMCPMC13065674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.